about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

Med­i­ci­No­va flops in PhII metham­phet­a­mine de­pen­dence tri­al, stock slips

8 years ago
R&D

Chi­nese on­col­o­gy start­up Ada­gene clos­es $50M Se­ries C led by Se­quoia Cap­i­tal

8 years ago
Financing
Startups

Iran­ian hack­ers steal aca­d­e­m­ic re­search worth bil­lions from US uni­ver­si­ties, pri­vate com­pa­nies

8 years ago
Pharma

Shang­hai drug­mak­er Hua hauls in $117M megaround, with plans for hefty Hong Kong IPO

8 years ago
Financing

With Big Phar­ma castoffs in hand, Mereo files for $81M IPO; Lon­don's Verona sees stock surge on PhI­Ib COPD da­ta

8 years ago
News Briefing

Pro­tag­o­nist aborts lead ul­cer­a­tive col­i­tis pro­gram af­ter drug fiz­zles in PhI­Ib, stock craters

8 years ago
R&D

Gain­ing steam in PD-1/L1 race, Roche re­ports pos­i­tive PhI­II OS da­ta on Tecen­triq com­bo in NSCLC

8 years ago
R&D

Failed again: Sanofi's Abl­ynx re­ports PhII lu­pus flop

8 years ago
R&D

Beat­ing out mar­ket lead­ers in PhII, an­tibi­ot­ic-mak­er Al­le­cra read­ies for Phase III tri­als

8 years ago
R&D

Helsinn buys glob­al rights for skin can­cer drug from Acte­lion; Ake­bia reels in more cash for vadadu­s­tat; EMA slams ...

8 years ago
News Briefing

Backed in part by Roche, Den­mark's NMD gets $47M to run or­phan neu­ro­mus­cu­lar dis­ease tri­als

8 years ago
Financing
Startups

In a blow to its biggest rev­enue dri­ver, In­di­v­ior los­es patent bat­tle with gener­ics mak­er Alvo­gen

8 years ago
Pharma

Mor­phoSys files for $150M IPO to fu­el its hope­ful DL­B­CL drug launch

8 years ago
Financing

An­oth­er im­munome­tab­o­lism deal? Johns Hop­kins spin­out Dra­cen lands $36M in­vest­ment from Deer­field

8 years ago
Financing

Uni­corn Mod­er­na joins line­up to list on Hong Kong's ex­change; Proces­sa li­cens­es com­pound from Con­cert

8 years ago
News Briefing

Sun Phar­ma screech­es to the pso­ri­a­sis fin­ish line with FDA OK of Ilumya. Too bad ri­vals J&J and oth­ers beat them to ...

8 years ago
Pharma

Third Rock de­buts im­munome­tab­o­lism start­up Rheos with $60M launch round

8 years ago
Financing
Startups

Cash­ing in on PhII tri­al suc­cess, Are­na to raise $353M to fu­el PhI­II etrasi­mod/ra­linepag tri­als

8 years ago
R&D

NY­C's biotech scene gets cash and of­fice space with Bea­con's new in­cu­ba­tor

8 years ago
Pharma

An­oth­er mega-start­up: Chi­na in­vestors back TCR2's $125M cash round to fu­el a pre­clin­i­cal as­sault on sol­id tu­mors

8 years ago
Financing

GSK launch­es PhI­II lu­pus com­bo study with Benlysta/rit­ux­imab; Ci­pher snatch­es Cana­di­an drug port­fo­lio from Car­diome

8 years ago
News Briefing

Are­na bounces back. Stock soars on ozan­i­mod ri­val's PhII suc­cess

8 years ago
R&D

Cidara touts 'pos­i­tive' PhII tri­al da­ta for an­ti­fun­gal, shares yo-yo on the news

8 years ago
R&D

Heron's pain drug nails PhI­II, prep­ping the com­pa­ny for NDA lat­er this year

8 years ago
R&D
First page Previous page 6789101112 Next page Last page
A service from the Financial Times